Living cells engineered to fight disease have transformed some blood cancers and are being pushed toward solid tumors, autoimmunity, and off-the-shelf manufacturing.
Sources: [1]Reference 1FDA approval of first CAR-T therapy (Kymriah)U.S. FDA, 2017First approved CAR-T cell therapy in the United States.[2]Reference 2CAR-T in refractory autoimmune diseaseMüller et al., NEJM, 2024Reported durable responses in severe autoimmune disease.
Key facts
- Portal
- Future Pharma
- Stage
- Clinical practice in defined indications
- Evidence
- Clinical practice
- Reversible
- Difficult to reverse
- Reviewed
- Jun 2026
- Read time
- 8 min
Contents
Page status
Manufacturing cost and speed · Serious immune toxicities
Key takeaways
- CAR-TTermCAR-TA therapy using a patient's T cells engineered to recognize and attack cancer, a living-cell treatment.In glossary → therapies produce durable remissions in some blood cancers that resisted other treatment.
- Solid tumors and autoimmune disease are the expansion fronts, with early autoimmune results notable.
- Cost, manufacturing, and serious immune toxicities constrain access and scale.
How engineered cells work
In CAR-TTermCAR-TA therapy using a patient's T cells engineered to recognize and attack cancer, a living-cell treatment.In glossary → therapy, a patient's T cells are collected, engineered to express a receptor that recognizes a cancer marker, expanded, and reinfused. The living drug then proliferates and persists, attacking cells carrying the target.
The same logic extends to other cell types and targets: engineered T cells against autoimmune B cells, natural killer cells, and stem-cell-derived products intended to be manufactured in advance rather than made per patient.
Frontier and constraints
The frontier is beyond blood cancer: durable responses in refractory autoimmune disease have drawn intense interest, and solid-tumor programs are working against a hostile tumor environment and antigen escape.
The constraints are practical. Bespoke manufacturing is slow and expensive, toxicities such as cytokine release require specialized centers, and off-the-shelf allogeneic products must solve rejection and persistence. Scaling access is as much a manufacturing problem as a biology problem.
Open questions
- Can allogeneic 'off-the-shelf' products match bespoke cells on durability?
- Will cell therapy work against common solid tumors, not just blood cancers?
Watchlist
Signals that would move this entry along the evidence scale.
Key terms
References
- FDA approval of first CAR-T therapy (Kymriah). U.S. FDA, 2017 First approved CAR-T cell therapy in the United States.
- CAR-T in refractory autoimmune disease. Müller et al., NEJM, 2024 Reported durable responses in severe autoimmune disease.
Cite this page
Future Human Atlas. “Engineered Cell Therapies.” Last reviewed Jun 2026. https://futurehumanwiki.com/articles/cell-therapies